Vesilute
Also known as: ED, Glu-Asp, L-Glu-L-Asp, Bladder Peptide
ED Dipeptide | Bladder & Urinary Tract Bioregulator
Overview
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute may help regulate smooth muscle function, enhance tissue blood flow, and support cellular regeneration in urogenital tissues. It is distinct from Vesugen (KED tripeptide), which targets vascular endothelium.
Key benefits
- Supports bladder and urinary tract function
- May improve prostate health in men
- Regulates smooth muscle function
- Enhances pelvic tissue blood flow
- Supports cellular regeneration
- Part of comprehensive Khavinson bioregulator protocols
- Well-tolerated in research
- Oral bioavailability as small dipeptide
Mechanism of action
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.
Molecular data
- Type
- Dipeptide bioregulator
- Half-life
- Not established
Sequence
Glu-Asp (ED)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Urinary Tract Health
Prostate Health (Men)
Anti-Aging Protocol
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10-20 mg | Daily for 10-20 days | — |
| — | 20 mg | 2-3 cycles yearly | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10-20 mg | Daily for 10-20 days | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated
- Injection site reactions (mild, if injectable)
- Minimal reported side effects
Rare side effects
- Allergic reactions (rare)
Contraindications
- Known hypersensitivity to peptide components
- Active urinary tract infection (treat first)
- Pregnancy or breastfeeding
- Prostate cancer (consult physician)
Monitoring
- Urinary symptoms and patterns
- Prostate health markers (PSA) if appropriate
- General well-being